Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

Table 2 Schedules of treatment in patients with HBV or HCV infection

Schedules of treatment [#]	Isolated HBcAb positive (23 patients)	HBcAb/HBsAb positive (36 patients)	HCV-Ab positive (15 patients)
Conventional therapy
MTX, n.	3	5	0
Duration, months (mean ± SD)	11 ± 7,54	24 ± 23,62	-
Cyclosporine, n.	0	4	4
Duration, months (mean ± SD)	-	5,75 ± 4,5	20,25 ± 10,34
MTX + Cyclosporine, n.	2	5	5
Duration, months (mean ± SD)	12	26,4 ± 21,46	30,4 ± 22,19
Conventional > Biological ^* therapy, n.	16	18	6
Duration, months (mean ± SD)	33,8 ± 16,9	48,1 ± 26,55	46 ± 34,77
Conventional > Biological ^* therapy + MTX, n.	2	4	0
Duration, months (mean ± SD)	35,5 ± 4,94	90,75 ± 65,06	-

^*Adalimumab, etanercept, infliximab, golimumab, ustekinumab.
[#] The treatment schedule was standardized, the doses were used as follows.
● MTX (7.5 vs15 mg/ week -per os or intramuscular injections).
● Cyclosporine (2.5 vs 5 mg/prokilo/die- per os).
● Adalimumab (40 mg every other week-subcutaneous injections).
● Etanercept (50 mg weekly- subcutaneous injections).
● Infliximab (5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks-endovenous infusion).
● Golimumab (50 mg monthly-subcutaneus injections).
● Ustekinumab ( For patients weighing ≤100 kg (220 lbs), the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. For patients weighing >100 kg (220 lbs), the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. – subcutaneous injections).
The data in bold represent "macro-categories", while the data not in bold represent their "sub-categories".

ISSN: 1471-230X